Skip to content
0032-spray

AdaptDx Disinfecting Recommendations

The AdaptDx Pro and Theia will change the future of AMD care because they make it easier for eye care professionals to test more patients and diagnose disease at an earlier stage.

ClaudioLagunas Claudio Lagunas, OD View all testimonials

For Practices

Subclinical AMD Detection

Research reveals that impaired dark adaptation is the earliest biomarker of AMD. Diagnosis at the subclinical level is the best chance to preserve vision.

For Patients

Protect Your Eyesight

Talking to your eye doctor about risk factors or trouble seeing at night may help detect macular degeneration early enough to hopefully delay progression of disease.

Breakthrough Technology Meets High-Touch Patient Care

Measuring dark adaptation speed with the AdaptDx Pro® can be useful in diagnosing AMD at the subclinical stage and managing this progressive disease with the hope of preventing unnecessary vision loss.

The AdaptDx Pro is amazing for two primary reasons. One, the portability of it is phenomenal. The other piece that’s critical is that Theia, the onboard AI tech, provides the instructions for the test, so patients get consistent instructions every time.

RyanPowell Ryan Powell, OD View all testimonials

Latest News & Upcoming Events

View More
Article: August 10, 2021 | Women in Optometry

How “Macula Mondays” Educates Patients About AMD in a Fun Environment

Jessica Marshall, OD, of Holmdel, New Jersey, takes the discussion about AMD out of the exam room and into everyday conversation with "Macula Mondays."

Article: August 2, 2021 | Primary Care Optometry News

Current AMD Research Impacts Clinical Practice

During the COVID slowdown, researchers seem to have sped up publishing breakthrough research on age-related macular degeneration. Much of this can be applied to real-life optometric practice.

Our Blog: August 1, 2021

5 Tips for Recommending Smoking Cessation Programs

Dr. Timothy Earley shares tips on how to talk to patients about smoking cessation, the biggest modifiable risk factor for AMD, and how to motivate them to quit.